Acute generalized exanthematous pustulosis (AGEP)

  • 5min
  • May. 2022
  • Supported by
    • La Roche-Posay

Therapeutic classes inducing this adverse event
Antiangiogenic agent, BRAF inhibitor, CTLA4 inhibitor, Chemotherapy, Cyclin-dependent kinase 4/6 inhibitor, EGFR inhibitor, Hormone therapy, KIT inhibitor, MEK inhibitor, PD-1 inhibitor, RAF inhibitor, Radiotherapy, SMO inhibitor, mTOR inhibitor

Acute generalized exanthematous pustulosis
Widespread erythema with superficial micropustules, predominantly in skin folds, fever, increased neutrophils
Widespread erythema with superficial micropustules, predominantly in skin folds, fever, increased neutrophils

Browse for more adverse events